Photys Therapeutics is pioneering phosphorylation-inducing chimeric small molecule medicines (PHICS) that direct and repair protein phosphorylation. PHICS work via induced proximity to enhance pairing of specific kinases with disease target proteins and can induce precise phosphorylation at native and/or non-native sites. The approach aims to modulate protein functions including activation, stabilization, localization, trafficking, degradation, inactivation, and phospho-antigen presentation, expanding beyond degradation-focused bifunctional modalities. Photys intends to apply its PHICS platform to cancer, immune, metabolic, and rare diseases and to build a broad pipeline of therapeutics. The company was founded by Longwood Fund and Dr. Amit Choudhary and lists Brian Fenton as President and CEO and Edward Holson as co-founder and CSO. Photys announced a $75 million Series A to advance its PHICS platform.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2022